Literature DB >> 19435422

Endothelial nitric oxide synthase polymorphisms and haplotypes in Amerindians.

Marcelo R Luizon1, Tatiane C Izidoro-Toledo, Aguinaldo L Simoes, Jose E Tanus-Santos.   

Abstract

Interethnic disparities in the distribution of endothelial nitric oxide synthase (eNOS) polymorphisms may affect nitric oxide (NO)-mediated effects of and responses to drugs. While there are differences between black and white subjects there is no information regarding the distribution of eNOS gene alleles and haplotypes in Amerindians. We studied three clinically relevant eNOS polymorphisms (T(-786)C in the promoter, a variable number of tandem repeats in intron 4, and the Glu298Asp in exon 7) and eNOS haplotypes in 170 Amerindians from three tribes of the Brazilian Amazon. The results were compared with previous findings for black and white Brazilians. The Asp298, C(-786), and 4a alleles were much less common in Amerindians (5.0%, 3.2%, and 4.1%, respectively) than in blacks (15.1%, 19.5%, and 32.0%, respectively) or whites (32.8%, 41.9%, and 17.9%, respectively) (p < 0.001). The haplotype including the most common alleles for each polymorphism was much more common in Amerindians (89%) than in blacks (45%) or whites (41%). Our findings are consistent with a lower genetic diversity in Amerindians compared with blacks and whites. These striking differences may be of major relevance for case-control association studies focusing on eNOS gene polymorphisms and may explain, at least in part, differences in the responses to cardiovascular drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19435422     DOI: 10.1089/dna.2009.0878

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  8 in total

1.  Endothelial nitric oxide synthase polymorphisms and haplotypes in genetic epidemiology and pharmacogenetics: remarks regarding a lack of association on the risk of myocardial infarction.

Authors:  Marcelo Rizzatti Luizon
Journal:  Mol Biol Rep       Date:  2014-01-07       Impact factor: 2.316

2.  Endothelial nitric oxide synthase intron 4 VNTR gene polymorphisms in European and African populations.

Authors:  Alfredo Santovito; Piero Cervella; Massimiliano Delpero
Journal:  Mol Biol Rep       Date:  2012-03-16       Impact factor: 2.316

Review 3.  Genetic determinants of cerebral vasospasm, delayed cerebral ischemia, and outcome after aneurysmal subarachnoid hemorrhage.

Authors:  Andrew F Ducruet; Paul R Gigante; Zachary L Hickman; Brad E Zacharia; Eric J Arias; Bartosz T Grobelny; Justin W Gorski; Stephan A Mayer; E Sander Connolly
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-13       Impact factor: 6.200

4.  Interaction among nitric oxide (NO)-related genes in migraine susceptibility.

Authors:  Flavia M Gonçalves; Marcelo R Luizon; Jose G Speciali; Alisson Martins-Oliveira; Fabiola Dach; Jose E Tanus-Santos
Journal:  Mol Cell Biochem       Date:  2012-08-04       Impact factor: 3.396

5.  Frequency of eNOS polymorphisms in the Colombian general population.

Authors:  Norma C Serrano; Luis A Díaz; Juan P Casas; Aroon D Hingorani; Daniel Moreno de Lucca; María C Páez
Journal:  BMC Genet       Date:  2010-06-20       Impact factor: 2.797

6.  Endothelial nitric oxide synthase polymorphisms and susceptibility to high-tension primary open-angle glaucoma in an Egyptian cohort.

Authors:  Wafaa A Emam; Haidy E Zidan; Bahaa-Eldin H Abdulhalim; Sherif A Dabour; Manar A Ghali; Aliaa T Kamal
Journal:  Mol Vis       Date:  2014-06-12       Impact factor: 2.367

7.  Endothelial nitric oxide synthase (-786T>C) polymorphism and migraine susceptibility: A meta-analysis.

Authors:  Han Dong; Zhi Hao Wang; Bin Dong; Ya Nan Hu; Hui Ying Zhao
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

Review 8.  Does eNOS derived nitric oxide protect the young from severe COVID-19 complications?

Authors:  Shou Ping Guan; Raymond Chee Seong Seet; Brian K Kennedy
Journal:  Ageing Res Rev       Date:  2020-11-04       Impact factor: 10.895

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.